Poster session

Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Dis

Retrieved on: 
Thursday, December 7, 2023

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the full abstract, titled “BMF-219: A novel therapeutic agent to reestablish functional beta cells and provide long-term glycemic control”, will be presented during the Abstract Oral Presentation Session as well as the Poster Session of the 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 7-9, 2023.

Key Points: 
  • BMF-219 is the first investigational agent to show durable glycemic control during off-treatment period after four weeks of dosing.
  • These data also further support the potential for BMF-219 as a disease modifying agent in type 2 diabetes.
  • Phase II consists of multiple ascending dose cohorts and dose durations and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

Retrieved on: 
Tuesday, November 7, 2023

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at the American College of Rheumatology (ACR) Convergence Annual Meeting held November 10-15 in San Diego, CA. The data demonstrate that MRT-6160, a novel, highly selective MGD targeting VAV1, attenuated disease progression in a murine collagen-induced arthritis (CIA) model.

Key Points: 
  • The data demonstrate that MRT-6160, a novel, highly selective MGD targeting VAV1, attenuated disease progression in a murine collagen-induced arthritis (CIA) model.
  • In vitro, MRT-6160 induced selective degradation of VAV1, and attenuated TCR- and BCR-mediated activation and function of primary human T- and B-cells.
  • In the CIA model, oral dosing of MRT-6160 elicited rapid VAV1 degradation across multiple tissues in a dose-dependent manner.
  • Over the course of 20 days, MRT-6160 significantly decreased disease progression and endpoint functional scores compared to vehicle and showed a trend towards superior activity compared to an anti-TNF antibody.

Dimagi to Present Cutting-Edge Strategies to Combat Housing Insecurity & Streamline Medication-Assisted Treatment at APHA 2023

Retrieved on: 
Thursday, November 2, 2023

CAMBRIDGE, Mass., Nov. 2, 2023 /PRNewswire/ -- Dimagi, a technology partner for public and community health, will present on its innovative programs deployed across various state partnerships at the 2023 American Public Health Association (APHA) conference. At the show, which will explore obstacles and opportunities in public health, Dimagi will discuss best practices and learned strategies from two successful programs in Vermont, which address barriers to care for individuals struggling with substance use disorder (SUD) and homelessness.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 2, 2023 /PRNewswire/ -- Dimagi , a technology partner for public and community health, will present on its innovative programs deployed across various state partnerships at the 2023 American Public Health Association (APHA) conference.
  • At the show, which will explore obstacles and opportunities in public health, Dimagi will discuss best practices and learned strategies from two successful programs in Vermont, which address barriers to care for individuals struggling with substance use disorder (SUD) and homelessness.
  • SUD affects more than 20 million Americans over the age of 12, and recent data shows that the number of homeless individuals in the U.S. has reached an all-time-high.
  • The poster will be presented as part of APHA's Opioids Poster Session 1 from 1:00 – 2:00 p.m. on Sunday, November 12 in the Poster Sessions area.

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Retrieved on: 
Thursday, September 21, 2023

BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today will present new preclinical data from SNS-101, a clinical-stage conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held on September 20 – 23, 2023 in Milan, Italy.

Key Points: 
  • “We believe these data further support the potential best-in-class PK and safety profile of SNS-101 and its ability to effectively target VISTA, a promising, but difficult-to-drug immune checkpoint,” said Edward van der Horst, Ph.D., Chief Scientific Officer of Sensei Biotherapeutics.
  • Paired with new mechanistic data showing SNS-101 can shift immunosuppressive macrophages towards an anti-tumor phenotype, we believe SNS-101 could provide a transformative treatment option for patients.
  • The expression of anti-tumor cytokines was correlated with a reduction in tumor size.
  • Sensei is evaluating SNS-101 in a Phase 1/2 clinical trial in patients with advanced solid tumors, and expects to report initial monotherapy pharmacokinetic and safety data by year-end 2023.

Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

Retrieved on: 
Monday, September 11, 2023

The conference is taking place October 2-3, 2023, in Galveston, Tex.

Key Points: 
  • The conference is taking place October 2-3, 2023, in Galveston, Tex.
  • The poster presentation is titled, Report of Phase 1 Part A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM).
  • In August 2023, Plus Therapeutics received an advance payment of grant funds of approximately $1.9 million, as planned, as part of its overall $17.6 million award contract , which CPRIT executed in September 2022.
  • The contract provides for funding from CPRIT over the three-year grant period starting on August 31, 2022, and follows the expected increase of development costs as the ReSPECT-LM clinical trial progresses to later stages.

Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023

JINAN, China, May 31, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting.

Key Points: 
  • JINAN, China, May 31, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting.
  • Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, were accepted in the Poster Session.
  • Two of the posters focus on the latest clinical research progress of Qilu Pharmaceutical's QL1706 in extensive-stage small cell lung cancer (ES-SCLC) and advanced hepatocellular carcinoma (HCC).
  • These findings support further investigation of QL1706 plus bevacizumab for first-line treatment of advanced HCC in a phase III clinical trial.

ClearPoint Neuro to Present Investigational Research and Showcase Novel Innovations at the 26th American Society of Gene & Cell Therapy Annual Meeting in Los Angeles

Retrieved on: 
Wednesday, May 10, 2023

Innovations to be showcased include the ClearPoint Maestro® Brain Model which will be shown at ASGCT for the first time since full market release.

Key Points: 
  • Innovations to be showcased include the ClearPoint Maestro® Brain Model which will be shown at ASGCT for the first time since full market release.
  • Maestro is designed to enable highly accurate ClearPoint interventions under MRI guidance by facilitating patient-specific, multi-modal fusion of anatomical information for accurate target identification and trajectory planning.
  • The software, which was originally licensed in 2020 from Philips, a global leader in health technology, gained FDA clearance in 2022.
  • Recent announcements related to Maestro include a partnership with NE Scientific to integrate a gene therapy infusion tool into the model .

QP Technologies™ Broadens Microelectronics Plastic-Package Portfolio

Retrieved on: 
Thursday, March 16, 2023

The 10x10mm eP TQFP package features a very thin profile (nominal 1mm thickness), ideal for tight-space applications and provides excellent thermal management.

Key Points: 
  • The 10x10mm eP TQFP package features a very thin profile (nominal 1mm thickness), ideal for tight-space applications and provides excellent thermal management.
  • Both packages are built at QP Technologies to JEDEC standards using industry-standard materials and tailored to accommodate the customer’s internal configuration needs.
  • Noted Kevin Coutts, director, sales and marketing for ASIC developer Device Engineering Inc. (DEI), “QP Technologies has previously delivered OCPP packages that met our customers’ standards for MSL performance.
  • 23 at 10:30 a.m., sales engineer Mike Strittmatter will present “Optimizing New Switch Technology for Mil-Aero Applications.”

Neuronetics Sponsors the 5th International Brain Stimulation Conference

Retrieved on: 
Tuesday, February 21, 2023

During a Poster Session at the Lisbon conference, Dr. Sackeim will present new findings from the NeuroStar Outcomes Registry, the world's largest registry of clinical outcomes in MDD.

Key Points: 
  • During a Poster Session at the Lisbon conference, Dr. Sackeim will present new findings from the NeuroStar Outcomes Registry, the world's largest registry of clinical outcomes in MDD.
  • In this sample of over 7,000 patients treated in community practices, longer treatment courses resulted in better depression outcomes.
  • The strong dose-response relationship between treatment sessions completed and improvement in depression symptoms was maintained when measured across different depression outcomes scores and all patient subgroups analyzed.
  • “We’re thrilled to participate in the 5th International Brain Stimulation Conference,” said Keith J. Sullivan, President and CEO of Neuronetics.

Halda Therapeutics unveils its first pipeline data for RIPTAC™ therapeutics, a new drug modality, at ASCO GU Symposium

Retrieved on: 
Tuesday, February 14, 2023

Halda has raised $76 million to date from investors, including Canaan Partners, Access Biotechnology, Elm Street Ventures, and Connecticut Innovations, to pioneer the new RIPTAC drug modality to treat cancer.

Key Points: 
  • Halda has raised $76 million to date from investors, including Canaan Partners, Access Biotechnology, Elm Street Ventures, and Connecticut Innovations, to pioneer the new RIPTAC drug modality to treat cancer.
  • "Halda’s new RIPTAC modality is an evolution of my lab’s multi-decade interest in heterobifunctional drugs,” said Professor Crews.
  • “RIPTAC therapeutics address a shortcoming shared by most current pharmaceutical modalities, namely, the reliance on oncogenic driver proteins which can result in drug resistance.
  • “Novel drug mechanisms are desperately needed to better address prostate cancer and the emergence of resistance to standard of care.